|Videos|December 20, 2022
Adjuvant Nivolumab Therapy for MIBC: Safety and Efficacy Data from CheckMate 274
Author(s)Terence Friedlander, MD
Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5